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Mechanisms, Prevention, and Treatment
of Atrial Fibrillation After Cardiac Surgery
Najmeddine Echahidi, MD,* Philippe Pibarot, DVM, PHD, FACC, FAHA,*
Gilles O’Hara, MD, FACC,* Patrick Mathieu, MD, FRCSC†
Ste-Foy, Quebec, Canada
Post-operative atrial fibrillation (POAF) is a frequent complication occurring in 30% to 50% of patients after car-
diac surgery. It is associated with an increased risk of mortality and morbidity, predisposes patients to a higher
risk of stroke, requires additional treatment, and increases the costs of the post-operative care. The aim of this
review is to present the current state of knowledge about the risk factors, mechanisms, prevention, and treat-
ment of this complication. In addition to the well known risk factors for the development of POAF such as age,
left atrial enlargement, and valvular surgery, new metabolic risk factors related to visceral obesity have been
identified. With regard to the prevention of POAF, beta-blocker drugs are effective and safe and can be used in
most patients, whereas amiodarone can be added in high-risk patients. Biatrial pacing was shown to be effec-
tive; however, its complexity might limit its application. Although there are only few data regarding the useful-
ness of magnesium, statins, N-3 polyunsaturated fatty acids, and corticosteroids, their addition to beta-blocker
drugs might be of benefit for further reducing POAF. Treatment includes the use of an AV nodal blocking agent
to achieve the rate control. If AF does not spontaneously convert to sinus rhythm within 24 h, anticoagulation
should be initiated and a rhythm control strategy should be attempted. More investigations are warranted to
explore mechanisms by which POAF occurs. This new knowledge would undoubtedly translate into a more effi-
cient prevention and treatment of this common post-operative complication that is associated with a major
health and economic burden. (J Am Coll Cardiol 2008;51:793–801) © 2008 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.10.043I
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dost-operative atrial fibrillation (POAF) is the most com-
on complication encountered after cardiac surgery. The
ncidence of POAF reported in previous studies varies
etween 20% and 50%, depending on definitions and
ethods of detection (1,2). The incidence of POAF has
ncreased continuously over the past decades, and this is
elieved to be due to the aging of the population undergoing
eart surgery. The pathophysiology of POAF after heart
urgery is not precisely known, but the mechanisms are
hought to be multifactorial. Different risk factors have been
eported, and many studies have evaluated the prophylactic
ffect of different pharmacologic or physical interventions.
he purpose of this review article is to discuss the recent
iscoveries about the potential mechanisms and the strate-
ies of prevention and treatment of POAF.
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esearch scholar from the Fonds de Recherches en Santé du Québec, Montreal,
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ccepted October 7, 2007.ncidence and Clinical Impact
he incidence of POAF is approximately 30% after isolated
oronary artery bypass grafting (CABG) surgery, 40% after
alve replacements or repair, and increases to approximately
0% after combined procedures. Furthermore, these figures
re expected to rise in the future, given that the population
ndergoing cardiac surgery is getting older and that the
ncidence of AF in the general population is strongly
ge-dependent.
Post-operative AF tends to occur within 2 to 4 days
fter the procedure, with a peak incidence on post-
perative day 2. Seventy percent of patients develop this
rrhythmia before the end of post-operative day 4 and
4% before the end of post-operative day 6 (3).
Although generally well tolerated and seen as a temporary
roblem related to surgery, POAF can be life threatening,
articularly in elderly patients and those with left ventricular
ysfunction in whom it is associated with significant mor-
idity (4) and mortality (5). Post-operative AF was reported
s a major morbid event (6), associated with increased
ost-operative thromboembolic risk and stroke (7), hemo-
ynamic compromise (8), ventricular dysrhythmias (1), and
atrogenic complications associated with therapeutic inter-
w
i
h
H
a
p
a
R
T
P
i
M
t
c
7
I
w
a
e
t
a
h
p
d
p
v
h
c
d
b
A
p
o
a
H
794 Echahidi et al. JACC Vol. 51, No. 8, 2008
Post-Operative Atrial Fibrillation: Review February 26, 2008:793–801ventions. Importantly, the risk
for perioperative stroke is ap-
proximately 3-fold higher for pa-
tients with POAF (1,5). More-
over, in a series of 3,855 patients
undergoing cardiac surgery, Al-
massi et al. (6) found that hospi-
tal mortality (6% vs. 3%) and
6-month mortality (9% vs. 4%)
were significantly higher in pa-
tients in whom POAF occurred.
Furthermore, the impact of
POAF on hospital resources is
substantial and was estimated to
lengthen hospital stay by 4.9 days,
ith an extra cost of $10,000 to $11,500 in hospital stay costs
n the U.S. (3). Knowing that there are at least 640,000 open
eart surgeries/year in the U.S. according to the American
eart Association (AHA) statistics in 2004 (9) and assuming
n incidence of 30% of POAF, the extra cost related to this
ost-operative complication could be conservatively estimated
t approximately $2 billion/year.
isk Factors
he most consistent predictor for the development of
OAF is advanced age (3,5,6) (Fig. 1). In a recent study
Abbreviations
and Acronyms
AF  atrial fibrillation
AV  atrioventricular
CABG  coronary artery
bypass graft
CI  confidence interval
HR  hazard ratio
OR  odds ratio
POAF  post-operative
atrial fibrillation
PUFAs  N-3
polyunsaturated fatty acids
Figure 1 Pathogenesis of POAF
The occurrence of post-operative atrial fibrillation (POAF) requires the presence of
resulting from the dispersion of atrial refractoriness. The latter requires an atrial s
disposing factors (advanced age, hypertension, diabetes, obesity, left atrial enlarg
tors such as atrial ischemia and surgical atrial injury might also contribute to the d
to play an important role. Finally, genetic factors likely predispose some patients t
such as an atrial premature contraction, electrolyte imbalance, and/or enhanced anvestigating the effect of age on the incidence of POAF,
athew et al. (10) have documented that for every decade
here is a 75% increase in the odds of developing POAF and
oncluded that, on the basis of age alone, anyone older than
0 years is considered to be at high risk for developing AF.
t is indeed well documented that advanced age is associated
ith degenerative and inflammatory modifications in atrial
natomy (dilation, fibrosis), which cause alterations in atrial
lectrophysiological properties (shortness of effective refrac-
ory period, dispersion of refractoriness and conduction,
bnormal automaticity, and anisotropic conduction) (11). It
as been demonstrated that these latter processes act as
otential substrates for POAF (12).
In addition to older age, many other risk factors for the
evelopment of POAF have been identified, including a
revious history of AF, male gender, decreased left-
entricular ejection fraction, left atrial enlargement, valvular
eart surgery, chronic obstructive pulmonary disease,
hronic renal failure, diabetes mellitus, and rheumatic heart
isease (1,5,10,13) (Fig. 1). More recently, obesity has also
een shown to be an independent predictor of new-onset
F in the general population (14) and in cardiac surgery
atients (15,16). In a recent study (16), we reported that
besity is a powerful risk factor for the occurrence of POAF
fter isolated CABG surgery in patients older than 50 years.
owever, in the younger population this association was not
ctrophysiological substrate that is the consequence of multiple re-entry wavelets
al substrate, which might be the consequence of an association of multiple pre-
, and left ventricular hypertrophy). Alternatively, operative and post-operative fac-
pment of the structural substrate. Inflammation and oxidative stress also seem
development of POAF. Once these conditions are present, a triggering factor
rgic or vagal stimulation will initiate POAF.an ele
tructur
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February 26, 2008:793–801 Post-Operative Atrial Fibrillation: Reviewbserved, and the metabolic syndrome was the only meta-
olic risk factor to be independently associated with POAF.
athophysiology and Mechanisms
he underlying mechanisms involved in POAF develop-
ent are multifactorial and are for the moment far from
eing fully elucidated. However, some causative mecha-
isms have been proposed that include pericardial inflam-
ation, excessive production of catecholamines, autonomic
mbalance during the post-operative period, and interstitial
obilization of fluid with resultant changes in volume,
ressure, and neurohumoral environment (Fig. 1). These
actors might alter the atrial refractoriness and slow atrial
onduction. Multiple re-entry wavelets resulting from the
ispersion of atrial refractoriness seem to be the electrophys-
ological mechanism of POAF (17,18). However, one
mportant question remains as to why there is an interindi-
idual susceptibility to POAF. At least one possible answer
s that patients with a structural substrate before operation
nd thus prone to atrial electrical re-entry are more vulner-
ble to physiological perturbations that are encountered in
he post-operative period (1). An alternative explanation is
hat this substrate is created as a result of the surgical
rocedure itself. It is indeed possible that the physical
lteration of the cardiac structure resulting from incision of
he atria or perioperative ischemia might increase cardiac
usceptibility to rhythm disturbances (19).
It is well known that neurohormonal activation increases
usceptibility to POAF (2,20). Increased sympathetic and
arasympathetic activation alter atrial refractoriness (e.g., a
hortening of the atrial effective refractory period), thus
ossibly contributing to the arrhythmia substrate (21). It has
een reported by Hogue et al. (22) that patients developing
OAF have either higher or lower RR interval variability,
uggesting that increased sympathetic or vagal tone occurs
efore arrhythmia onset. These findings suggest that inter-
entions that would modulate both the sympathetic and
arasympathetic nervous systems might be beneficial in
uppressing this post-operative arrhythmia.
dapted From the ACC/AHA/ESC 2006 Guidelines for the Manage
Table 1 Adapted From the ACC/AHA/ESC 2006 Guidelines for
Indication Class I Unless contraindicated, treatment with an oral beta-b
patients undergoing cardiac surgery
Administration of AV nodal blocking agents is recom
POAF
Indication Class IIa Pre-operative administration of amiodarone reduces
surgery and represents appropriate prophylactic th
It is reasonable to restore sinus rhythm by pharmaco
cardioversion in patients who develop POAF, as ad
It is reasonable to administer antiarrhythmic medica
with recurrent or refractory POAF, as recommende
It is reasonable to administer antithrombotic medica
nonsurgical patients
Indication Class IIb Prophylactic administration of sotalol might be consi
surgerydapted from Fuster et al. (32).
ACC  American College of Cardiology; AF  atrial fibrillation; AHA  American Heart Association; AVAlso, there is now an increasing body of evidence that
nflammation plays an important role in the pathogenesis of
OAF. Two recent studies have shown that inflammation
an alter atrial conduction, facilitating re-entry and then
redisposing to the development of POAF (23,24) (Fig. 1).
t is well known that extracorporeal circulation is character-
zed by a systemic inflammatory response, which might be
n part responsible for the occurrence of POAF. Interest-
ngly, it has been reported recently that the leukocytosis,
hich is usually encountered in the days after cardiopulmo-
ary bypass, is an independent predictor for the occurrence
f POAF (25,26).
Obesity is associated with higher cardiac output require-
ent, higher left ventricular mass, and larger left atrial size
27) (Fig. 1). These factors might predispose to the devel-
pment of POAF.
In addition to the aforementioned processes, other patho-
hysiological mechanisms might also intervene as contributing
actors in the development of POAF, including volume over-
oad (28), genetic predisposition assessed by the interleukin-6
romoter gene variant (29), alterations in atrial oxidative stress
30), and increased expression of the gap-junctional protein
onnexin 40 (31) (Fig. 1).
revention
any studies have evaluated the effectiveness of pharma-
ologic and nonpharmacologic interventions to prevent
r decrease the high incidence of POAF. Recent guide-
ines for the prevention and management of POAF were
ublished in 2006 jointly by the American College of
ardiology, the AHA, and the European Society of
ardiology (32) (Table 1).
eta-blocker drugs. Because sympathetic activation
ight facilitate POAF in susceptible patients, and given
he increased sympathetic tone in patients undergoing
ardiac surgery, beta-blocker drugs have been so far the
ost studied drugs for the prevention of this post-
perative arrhythmia.
of AF After Cardiac Surgery
Management of AF After Cardiac Surgery
drug to prevent POAF is recommended for Level of Evidence: A
d to achieve rate control in patients who develop Level of Evidence: B
idence of AF in patients undergoing cardiac
for patients at high risk for POAF
Level of Evidence: A
ardioversion with ibutilide or direct-current
for nonsurgical patients
Level of Evidence: B
an attempt to maintain sinus rhythm in patients
ther patients who develop AF
Level of Evidence: B
patients who develop POAF, as recommended for Level of Evidence: B
for patients at risk of developing AF after cardiac Level of Evidence: Bment
the
locker
mende
the inc
erapy
logic c
vised
tions in
d for o
tion in
dered atrioventricular; ESC  European Society of Cardiology; POAF  post-operative AF.
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Post-Operative Atrial Fibrillation: Review February 26, 2008:793–801Several clinical trials have evaluated the effect of various
eta-blocker drugs on the incidence of POAF (33–35),
howing an overall reduction of this complication. But these
tudies varied widely in their study design, including the use
f different types of beta-blocker drugs, different popula-
ions and surgical interventions, and different modalities for
efining and detecting POAF. However, most of these
tudies were consistent in showing a significant reduction in
he incidence of POAF. In a recent meta-analysis, Crystal
t al. (36) found that beta-blocker drugs had the greatest
agnitude of effect across 28 trials (4,074 patients) with an
dds ratio (OR) of 0.35, 95% confidence interval (CI) 0.26
o 0.49. In addition, Andrews et al. (2) reported, in another
eta-analysis of 24 trials limited to patients with ejection
raction 30% undergoing CABG, that prophylactic ad-
inistration of beta-blocker drugs was associated with a
rotection against supraventricular tachycardia with an OR
f 0.28, 95% CI 0.21 to 0.36.
In the meta-analysis by Burgess et al. (37), the authors
eported that, despite the fact that beta-blocker drugs have
hown an overall reduction in AF, there was a significant
eterogeneity among the trials for beta-blocker therapy.
ifferences between the treated and the control groups were
uch stronger for those trials mandating discontinuation of
onstudy beta-blocker drugs before surgery. The results
rom this meta-analysis suggested that some but not all of
he effect associated with beta-blocker drugs might have
een due to beta-blocker withdrawal at the time of surgery.
hese data strongly suggest that physicians should not
iscontinue beta-blocker drugs before cardiac surgery.
otalol. Sotalol is a beta-blocker drug that also has impor-
ant class III antiarrhythmic drug effects. Numerous studies
ave evaluated sotalol prophylaxis on the incidence of
OAF. In a meta-analysis (37) of 14 trials including 2,583
atients that compared beta-blocker or placebo, Burgess
t al. found that sotalol was more effective in reducing
OAF than either other beta-blocker medication or pla-
ebo. Sotalol therefore seems to offer significant additional
rotection over standard beta-blocker drugs. However, one
rial comparing sotalol with metoprolol in doses considered
o provide equivalent beta-blockade reported a higher prev-
lence of post-operative bradyarrhythmias with sotalol pro-
hylaxis (38). In this trial, more patients withdrew from
otalol treatment, owing to side effects (predominantly
ypotension and bradycardia), than placebo (6.0% vs. 1.9%;
 0.004).
miodarone. Amiodarone is a Vaughan–Williams class III
rug, which also has alpha- and beta-adrenergic blocking
roperties that might attenuate sympathetic overstimulation
een in patients undergoing cardiac surgery (39). In a
andomized trial including 124 patients undergoing a com-
lex cardiac surgery, amiodarone administered orally at least
week pre-operatively significantly reduced the incidence of
OAF, from 53% in the placebo group to 25% in the
reated group (p  0.003) (40). In another recent trial, the
RCH (Amiodarone Reduction in Coronary Heart) trial r41), including 300 patients, post-operative intravenous
dministration of amiodarone was associated with a lower
ncidence of POAF (35%) compared with the placebo arm
47%) (p  0.01). Although the safety of amiodarone
dministration in the cardiac surgical patients has been
uestioned by some authors, a compelling evidence of the
fficacy and safety of amiodarone has been demonstrated by
he PAPABEAR (Prophylactic Oral Amiodarone for the
revention of Arrhythmias that Begin Early After Revas-
ularization, Valve Replacement, or Repair) trial (42). In
his large-scale study, a 13-day perioperative course of oral
miodarone was well tolerated and effective for the preven-
ion of post-operative atrial tachyarrhythmia after a cardiac
urgery. However, there seems to be some heterogeneity
mong the amiodarone trials, with stronger effects found
mong patients who were not simultaneously treated with
eta-blocker drugs. A recent meta-analysis of 18 random-
zed controlled trials including 1,736 receiving amiodarone
ersus 1,672 receiving placebo found that amiodarone was
ssociated with an increased risk of bradycardia and hypo-
ension, particularly when administered intravenously (43).
he greatest risk in the occurrence of these adverse events
ccurred when using regimens containing intravenous ami-
darone, initiating prophylaxis during the post-operative
eriod, and using regimens with average daily doses exceed-
ng 1 g. The concomitant use of beta-blocker drugs might
lso exacerbate these adverse effects.
trial pacing. The utility of prophylactic atrial pacing to
revent AF after heart surgery is based on the fact that
acing is thought to favorably influence intra-atrial conduc-
ion and atrial refractoriness (44). There are several mech-
nisms by which atrial pacing might prevent AF, including
he following: 1) reduction of the bradycardia-induced
ispersion of atrial repolarization, which contributes to the
lectrophysiologic substrate for AF (45); 2) atrial overdrive
uppression of atrial premature beats and runs of supraven-
ricular premature beats, thus avoiding the trigger for AF
46); and 3) dual-site atrial pacing might change atrial
ctivation patterns, thus preventing the development of
ntra-atrial re-entry (47).
The effect of prophylactic pacing has been investigated in a
umber of trials. Meta-analyses of these clinical trials
37,48,49) have consistently shown that single- or dual-site
trial pacing significantly reduces the risk of new-onset POAF.
owever, the number of enrolled patients was small, and the
acing sites and protocols varied widely among studies. In a
andomized trial, biatrial overdrive pacing in patients under-
oing CABG was shown to be more effective in preventing
OAF than single-site atrial pacing (12.5% vs. 36%) (50).
owever, this trial included a small number of patients, and
his intervention has significant limitations. Indeed, the
ajor adverse effect of prophylactic atrial pacing is its
otential proarrhythmic effect, which might be precipitated
y inappropriate sensing or loss of pacing through tempo-
ary wires (51). Thus, further studies are needed to deter-
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February 26, 2008:793–801 Post-Operative Atrial Fibrillation: Reviewine the usefulness of this method for the prevention of
OAF.
ther medications. DIGOXIN. Once widely used, digoxin
s a preventive measure of POAF has been abandoned,
wing to its inefficacy. Indeed, recent meta-analyses consis-
ently found that the pre-operative use of digoxin was not
fficient at reducing POAF incidence (2,52).
ALCIUM-CHANNEL BLOCKER DRUGS. Numerous studies
ave evaluated nondihydropyridine calcium-channel blocker
rugs. A recent meta-analysis of these trials showed that
alcium-channel blocker drugs reduce supraventricular
achyarrhythmia risk (OR 0.62; 95% CI 0.41 to 0.93) (53).
owever, in some studies, the perioperative use of these
rugs was associated with an increased incidence of atrio-
entricular (AV) block and low output syndrome, which
ight be related to the negative chronotropic and inotropic
ffect of this class of drug. Hence, although calcium-channel
locker drugs might have a role for POAF prophylaxis, their
sage should be considered with caution until more data on
heir safety profile become available.
AGNESIUM. Although still controversial, serum hypomag-
esemia is common after cardiac surgery (54) and is asso-
iated with post-operative atrial tachyarrhythmias (55).
ome clinical trials have assessed the efficacy of magnesium
dministration for the prevention of POAF. A meta-
nalysis (56) concluded that magnesium administration was
ffective for reducing POAF with a similar efficacy to
ommon antiarrhythmic drugs. However, the studies in-
luded in this analysis included a small number of patients,
nd the design varied among the different studies, thus
imiting the interpretation of the results.
TATINS. Given that observational studies had previously
uggested that patients under statin therapy have a lower
ncidence of POAF after CABG (57) and that statins have
een shown to reduce inflammation in patients with coro-
ary artery disease, some investigators examined the useful-
ess of statins for the prevention of POAF. Recently, the
rospective randomized study ARMYDA-3 (Atorvastatin
or Reduction of MYocardial Dysrhythmia After cardiac
urgery) (58) has demonstrated that treatment with Ator-
astatin 40 mg/day started 7 days before elective cardiac
urgery under cardiopulmonary bypass and continued in the
ost-operative period significantly reduces the occurrence of
OAF by 61%.
-3 POLYUNSATURATED FATTY ACIDS (PUFA). Recent exper-
mental studies in rats have shown that PUFAs have
ignificant antiarrhythmic effects on the atrial muscle (59).
n another recent experimental study on dogs, a team from
ur institution (60) reported that oral treatment with fish
ils reduces vulnerability to induction of AF. They found
hat modulation of cardiac connexin was probably the
ontributing mechanism to the antiarrhythmic effects of fish
il supplementation. Furthermore, in the general popula-
ion, consumption of fish, inducing high plasma PUFA ooncentration, has been associated with a lower incidence of
F in a 12-year follow-up study (61). Of particular signif-
cance, Calo et al. (62), in a randomized controlled trial of
60 patients undergoing elective CABG, found that PUFAs
upplementation significantly reduced the incidence of
OAF, with an effect similar to that obtained with beta-
locker drugs, sotalol, or amiodarone.
NTI-INFLAMMATORY AGENTS. In a recent study,
heruku et al. (63) randomized 100 patients undergoing
ABG to 2 arms: the first arm received 30 mg ketorolac
ntravenously every 6 h until the patients were able to
ake oral medications, at which point they were switched
o 600 mg ibuprofen orally 3 times/day; the other arm
eceived conventional treatment. Atrial fibrillation oc-
urred in 14 patients (28.6%) in the conventional treat-
ent arm versus 5 patients (9.8%) in the anti-
nflammatory medication group (p  0.017). The authors
oncluded that nonsteroidal anti-inflammatory medica-
ions are effective in significantly reducing the incidence
f AF after CABG. However, the risk versus benefit ratio
f such prophylactic strategy remains uncertain, given
hat these agents are potentially associated with nephro-
oxicity, which might be exacerbated in the post-
perative period, especially in elderly patients.
Interestingly, in a recent multicenter trial (64) 241
onsecutive patients undergoing cardiac surgery were
andomized to receive either 100 mg hydrocortisone or a
lacebo. The incidence of POAF during the first 84 h
as significantly lower in the hydrocortisone group (36 of
20 [30%]) than in the placebo group (58 of 121 [48%],
nd the adjusted HR was 0.54; 95% CI 0.35 to 0.83;
 0.004).
These promising results might open new avenues in the
rophylactic regimen aiming at the reduction of POAF.
owever, further studies comparing various doses and admin-
stration times are still necessary before firm conclusion can be
ade with regard to the preventive role and safety of calcium-
hannel blocker drugs, magnesium, statins, PUFAs, and anti-
nflammatory agents.
mpact of the prevention strategies on post-operative
utcomes. Although several pharmacologic or nonpharma-
ologic interventions have been shown to significantly
educe the incidence of POAF, it is still controversial
hether or not these interventions translate into a signifi-
ant reduction of stroke or other perioperative complica-
ions. Moreover, the effect of these interventions on the
ength of hospital stay and on economic costs also remains
ontroversial. However, a few studies have reported a
inimal but significant reduction in hospital stay with
miodarone, magnesium, or biatrial pacing combined with
eta-blocker drugs (48). Hence, it is possible that adverse
ide effects of some interventions might balance or outweigh
he benefits of POAF suppression on post-operative
utcomes.
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s a general rule, the management of medical comorbidities
e.g., hypoxia) and the correction of underlying electrolyte
mbalance (especially potassium and magnesium) is part of
he management strategy for the prevention and treatment
f POAF.
Although POAF can be transient and generally self-
imiting, treatment is indicated for patients who remain
ymptomatic, are hemodynamically unstable, and develop
ardiac ischemia or heart failure. Conventional treatment
trategies include prevention of thromboembolic events,
ontrol of the ventricular rate response, and restoring/
aintaining sinus rhythm. Currently the evidence suggests
trend toward a strategy of rhythm control over rate
ontrol. The advantages of rhythm control are a decreased
ime to cardioversion, prolonged maintenance of sinus
hythm, and decreased length of overall hospital stay (65).
ate control. The post-operative period is characterized by
ncreased adrenergic stress, and thus it might be difficult to
ontrol the ventricular rate in patients with POAF. Short-
cting beta-blocker agents are the therapy of choice,
articularly in ischemic heart disease, but they might be
oorly tolerated or relatively contraindicated in patients
ith known asthma or bronchospastic disease, congestive
eart failure, or AV conduction block (Table 2). Alter-
atively, other AV nodal blocking agents, such as the
ondihydropyridine calcium-channel blocker agents can
e used. Digoxin is less effective when adrenergic tone is
osage, Advantages, and Side Effects of Drugs Used for Rhythm C
Table 3 Dosage, Advantages, and Side Effects of Drugs Used f
Drugs Adult Dosage Advan
Amiodarone 2.5–5 mg/kg IV over 20 min then
15 mg/kg or 1.2 g over 24 h
Can be used in
severe LV dy
Procainamide 10–15 mg/kg IV up to 50 mg/min Therapeutic lev
achieved
Ibitulide 1 mg IV over 10 min, can repeat
after 10 min if no effect
Easy to use
osage, Advantages, and Side Effects of Drugs Used for Rate Cont
Table 2 Dosage, Advantages, and Side Effects of Drugs Used f
Drugs Adult Dosage
Digoxin 0.25–1.0 mg IV then 0.125–0.5
mg/day IV/PO
Beta-blocker drugs
Esmolol 500 g/kg over 1 min then
0.05–0.2 mg/kg/min
Atenolol 1–5 mg IV over 5 min repeat after
10 min then 50–100 mg b.i.d. PO
Metoprolol 1–5 mg IV over 2 min then
50–100 mg b.i.d. PO
Calcium-channel blocker drugs
Verapamil 2.5–10 mg IV over 2 min then
80–120 mg/day b.i.d. PO
Diltiazem 0.25 mg/kg IV over 2 min then
5–15 mg/h IV
VB  atrioventricular block; b.i.d.  twice daily; IV  intravenous; PO  by mouth; POAF  postV  intravenous; LV  left ventricular; POAF  post-operative atrial fibrillation.igh but might be used in patients with congestive heart
ailure. Amiodarone has also been reported to be effective
n controlling heart rate, and its intravenous administra-
ion has been associated with improved hemodynamic
tatus (66).
hythm control. In symptomatic patients or when ven-
ricular response is difficult to control, cardioversion might
e preferred, with the same precautions regarding antico-
gulation as in nonsurgical patients. Different agents might
e effective to convert AF to sinus rhythm (Table 3),
ncluding amiodarone (40), procainamide (67), ibutilide,
nd sotalol (68). In one study (69), ibutilide was more
ffective than a placebo for the treatment of POAF, but
olymorphic ventricular tachycardia has been reported and
ttributed to electrolyte imbalance. In the post-operative
eriod, sotalol’s beta-blocking action is particularly effective
t reducing the ventricular rate, and its proarrhythmic
oxicity is relatively infrequent, but this agent seems less
ffective than others for inducing cardioversion of AF.
lectrical cardioversion. Electrical cardioversion should
e urgently performed when POAF results in hemodynamic
nstability, acute heart failure, or myocardial ischemia and
lectively used to restore sinus rhythm after the first onset of
F when a pharmacologic attempt has failed to resume a
inus rhythm. Anterior-posterior placement of the paddles
s preferred, and the patient is sedated with a short-acting
nesthetic. A biphasic waveform shock is generally used and
s associated with the lowest energy, highest rates of
l in POAF
ythm Control in POAF
Side Effects
ts with
ion
Thyroid and hepatic dysfunction, torsades de pointes, pulmonary
fibrosis, photosensitivity, bradycardia
ickly Hypotension, fever, accumulates in renal failure, can worsen
heart failure, requires drug level monitoring
Torsades de pointes more frequent than amiodarone and
procainamide
POAF
te Control in POAF
Advantages Side Effects
e used in heart failure Nausea, AVB moderate effect in POAF
acting effect and short duration Might worsen congestive heart failure; can
cause bronchospasm, hypotension; AVB
onset of rate control (IV)
onset of rate control (IV)
acting effect Might worsen congestive heart failure, AVB
ive atrial fibrillation.ontro
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f cardioversion, either electrically or pharmacologically, is
hromboembolism, particularly when POAF has been
resent for more than 48 h. Whether guidelines for antico-
gulation before cardioversion in nonsurgical patients apply
o the post-surgical condition is not clear. In the general
opulation, anticoagulation for 3 to 4 weeks before cardio-
ersion is recommended for AF that has lasted for over 48 h.
n acceptable approach in the post-operative period would
e to perform a transesophageal echocardiographic exami-
ation to exclude mural thrombus, particularly in the left
trial appendage before cardioversion. Because atrial “stun-
ing” persists after cardioversion, anticoagulation is recom-
ended for 3 to 4 weeks after conversion of AF to sinus
hythm.
hromboembolism prevention. Post-operative AF is asso-
iated with an increased risk of perioperative strokes (71–72)
hat might be reduced by therapeutic anticoagulation. In
ontrast, anticoagulation in the post-operative period might
ncrease the risk of bleeding or cardiac tamponade (73). In this
ontext, the clinician must weigh the usually transient and
elf-limited duration of new-onset POAF against the poten-
ial for post-operative bleeding if anticoagulation therapy is
tarted. The increased risk of bleeding might indeed out-
eigh the benefits in reducing the risk of stroke in some
atients, especially those with the following risk factors:
dvanced age, uncontrolled hypertension, and history of
leeding.
No controlled trials have specifically evaluated the efficacy
nd safety of anticoagulation therapy for new-onset POAF,
hich often resolves spontaneously after 4 to 6 weeks. As a
eneral rule, anticoagulation is instituted for prolonged
48 h) and/or frequent POAF episode. The American
ollege of Chest Physicians recommends the use of anti-
oagulation therapy particularly for high-risk patients, such
s those with a history of stroke or transient ischemic attack
n whom atrial fibrillation develops after surgery. In these
atients, it is also recommended to pursue the anticoagula-
ion therapy for another 30 days after the return of a normal
inus rhythm (74).
onclusions
ost-operative AF after cardiac surgery is a highly frequent
omplication that leads to an increased risk of mortality and
orbidity, predisposes patients to a significantly higher risk
f thromboembolism and stroke, often requires additional
reatment, and substantially increases the costs of the
ost-operative care.
Currently, there is significant variation in the preventive
trategy of POAF. However, current evidence suggests that
eta-blocker drugs are effective and safe and can be used in
ost patients. Therefore, unless contraindicated, beta-
locker drugs should be continued perioperatively or initi-
ted in all patients. Amiodarone can be safely added in
atients at high-risk for AF. Biatrial pacing was shown to beffective; however, its complexity limits its application on a
ide-scale basis. Although there are only few data regarding
he usefulness of magnesium, statins, N-3 polyunsaturated
atty acids, and corticosteroids, their addition to a beta-
locker–based therapy might be of benefit for further
educing this post-operative arrhythmia.
When POAF occurs, an immediate electrical cardiover-
ion has to be performed for hemodynamically unstable
atients. For those who are hemodynamically stable, an AV
odal blocking agent should be used to achieve the ventric-
lar response control. If AF does not spontaneously convert
o sinus rhythm within 24 h, then a rhythm control strategy
hould be attempted with class III or Ic antiarrhythmic
rugs, associated with an early anticoagulation.
A better knowledge of the mechanisms implicated in
OAF would undoubtedly translate into a better prevention
f this common post-operative complication. In particular,
he recent demonstration of an independent association
etween POAF and metabolic conditions such as obesity,
etabolic syndrome, and diabetes certainly deserves further
echanistic studies to identify new druggable targets.
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